Washington, D.C. 20549

                                   FORM 8-K/A

                                 CURRENT REPORT
     Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)  October 9, 2009

                           Lightlake Therapeutics Inc.
- --------------------------------------------------------------------------------
             (Exact name of registrant as specified in its charter)

           Nevada                 333-139915                    N/A
- --------------------------------------------------------------------------------
 (State or other jurisdiction    (Commission              (I.R.S. Employer
      of incorporation)          File Number)             Identification No.)

     225-230 Queens Quay W, Toronto, ON                        M5J2Y7
- --------------------------------------------------------------------------------
  (Address of principal executive offices)                    (Zip Code)

Registrant's telephone number, including area code  416-841-5414

- --------------------------------------------------------------------------------
         (Former name or former address, if changed since last report.)

 Check the appropriate box below if the Form 8-K filing is intended to
 simultaneously satisfy the filing obligation of the registrant under any of the
 following provisions (see General Instruction A.2. below):

[ ]  Written communications pursuant to Rule 425 under the Securities Act (17
     CFR 230.425)

[ ]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
     CFR 240.14a-12)

[ ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the
     Exchange Act (17 CFR 240.14d-2(b))

[ ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the
     Exchange Act (17 CFR 240.13e-4(c))


Item 4.01    Changes in Registrant's Certifying Accountant.

On August 17, 2009, Madrona Ventures Inc. (the "Company") now known as Lightlake
Therapeutics Inc. dismissed its auditing firm of Dale Matheson Carr-Hilton
Labonte LLP. On the same date, August 17, 2009, the accounting firm of PS
Stephenson & Co., P.C., CPA was engaged as the Company's new independent
auditing firm. The decision to change auditing firms was approved by the board
of directors of the Company.

Over the past two fiscal years our former auditor's report on our financial
statements did not contain an adverse opinion, a disclaimer of opinion, or was
qualified or modified as to uncertainty, audit scope or accounting principles.
In that same period of time the Company did not have any disagreements with our
former auditing firm of Dale Matheson Carr-Hilton Labonte LLP on any matter of
accounting principles or practice, financial statement disclosure, or auditing
scope or procedure.

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Lightlake Therapeutics Inc. --------------------------- (Registrant) Date 10/09/2009 ---------- /s/ Seijin Ki ------------- (Signature) Director, President and Secretary

                                                                      Exhibit 16

October 5, 2009

Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549

Re: Madrona Ventures Inc.

Ladies and Gentlemen:

We are the former independent accountants for Madrona Ventures Inc. (the
"Company"). We have been furnished with a copy of the Company's response to Item
4.01 of Form 8-K disclosing our dismissal as independent public accountants of
the Company. We confirm our agreement with the statements made in such
disclosure insofar as they relate to our firm. We are not in a position to agree
or disagree with the statements in such disclosure regarding the appointment of
or consultations with new independent accountants by the Company.

Yours truly,


Dale Matheson Carr-Hilton LaBonte LLP
Chartered Accountants
Barry Hartley, CA